Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands

Fig. 3

Adjusted rate and odds ratios (95 % CI) for co-primary and secondary outcomes. ICS: inhaled corticosteroid; SABA, short-acting β2-agonist. *Adjusted for baseline exacerbations (ATS/ERS Definition, categorized), evidence of GERD and baseline asthma prescriptions (categorized); Adjusted for baseline Risk-domain asthma control, evidence of GERD and asthma diagnosis; Adjusted for evidence of rhinitis, evidence of GERD and baseline Risk-domain asthma control; §Adjusted for baseline SABA daily dose (µg)

Back to article page